SOUTH EASTON, Mass. — Pressure BioSciences, Inc. (Nasdaq:PBIO) (“PBI”) and Digilab, Inc. (“Digilab”) (together “the companies”) today announced that they have entered into a co-marketing/selling and research and development agreement. The companies intend to co-market and sell their respective product lines worldwide, including in industry publications, at scientific meetings, on each company’s website, through common collaborator studies, at key industry trade shows, and in visits to customer sites. PBI and Digilab also intend to explore ways to co-develop new instrumentation, accessories/modules for existing instrumentation, and consumables that combine the robotics and high throughput capabilities of Digilab products with the extraction, protein digestion, and other advantages of PBI’s Pressure Cycling Technology (“PCT”) Platform.

One of the most significant problems in protein studies today is the proper preparation of a sample prior to its analysis. Poor sample preparation can lead to inaccurate results. Digilab and PBI believe that a combination of their respective proprietary technology platforms will provide scientists with an improved, more reproducible, integrated workflow to better address important sample preparation issues that are routinely encountered by scientists in the estimated 80,000 biological research laboratories worldwide.

Mr. Sidney Braginsky, Chairman and CEO of Digilab, said: “We believe that Digilab’s suite of sample preparation, liquid handling, and identification products, coupled with PBI’s unique pressure-based technology platform and PCT products, will offer the research scientist greatly enhanced sample preparation tools with a higher degree of reproducibility, versatility, throughput, and overall quality than currently available. We believe this will result in increased sales and visibility for both Digilab and PBI.”

Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, said: “Digilab and PBI share the same sample preparation target market. We routinely find ourselves attending many of the same scientific meetings, advertising in many of the same media outlets, and collaborating with many of the same thought leaders in the field.”

Mr. Schumacher continued: “PBI’s sales and marketing activities are currently performed with four dedicated staff members and three distribution partners. These efforts will be greatly enhanced by the Digilab sales and marketing team of five staff members and their broad distribution network of over twenty distributors worldwide. Similarly, our sales and marketing team will assist Digilab in broadening the reach of their sales activities. Consequently, we believe that this alliance will greatly facilitate the introduction of our respective sample preparation product lines to research laboratories worldwide, but without the need to increase sales staff, marketing budgets, and time at scientific meetings. We believe this is a very cost-effective way to significantly increase market penetration and increase sales for both companies. We expect to begin to see these increased sales results during the first half of 2012.”

About Digilab, Inc.

Digilab, Inc. provides imaginative, value-adding solutions for scientific discovery in life sciences, analytical chemistry, and diagnostics markets. Products span DNA sample preparation systems for sequencing, protein and DNA micro arrayers, live cell arrayers, proteome preparation systems, nano & micro fluidic handling, and Raman compound identification. Digilab is identified by- and built on- the excellent reputation of its acquired brands including Genomic Solutions, Investigator, GeneMachines, Cartesian Dispensing Systems, BioRobotics, SpectraCode, and Maia Scientific. In addition, Digilab has developed its own live cell printer, the CellJet, and high throughput screening Raman reader, the Identity. These brands have well established global presence from the thousands of customers worldwide.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (Nasdaq:PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.